Drug Profile
NUC 7738
Alternative Names: NUC 7738Latest Information Update: 18 Oct 2023
Price :
$50
*
At a glance
- Originator Cardiff University
- Developer NuCana; University of St Andrews
- Class Antineoplastics; Nucleosides
- Mechanism of Action RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Lymphoma; Solid tumours
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 16 Oct 2023 Efficacy data from a phase-II clinical trials in Solid tumours released by NuCana
- 11 Oct 2023 Updated adverse events data from a phase I/II trial in Solid tumours and Lymphoma presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2023)
- 12 Sep 2022 Efficacy and adverse events data from a phase I/II trial in Solid tumours presented in an oral presentation at the European Society of Medical Oncology (ESMO-2022)